Key result
In patients with intracerebral hemorrhage, atrial fibrillation did not independently increase 3-month mortality after adjusting for antithrombotic pretreatment.
Why the study?
To analyze clinical differences between primary intracerebral hemorrhage patients with and without AF, and evaluate whether AF modifies the effect of antithrombotic pretreatment on outcomes.
Does antithrombotic pretreatment modify mortality and disability in patients with primary intracerebral hemorrhage with and without atrial fibrillation?
Observational (n=1,106)
Yes
Does antithrombotic pretreatment modify mortality and disability in patients with primary intracerebral hemorrhage with and without atrial fibrillation?
Answers are grounded in this paper and cite their sources.
AF not independently tied to ICH mortality after adjustment; leaves open whether antithrombotic pretreatment modifies outcomes by AF status.
Objective To analyze the clinical differences between patients with primary intracerebral hemorrhage (ICH) with and without atrial fibrillation (AF) and assess whether the effect of the antithrombotic pretreatment on outcome is modified by the presence of AF. Methods In this prospective observational study, researchers from 2 university hospitals included 1,106 consecutive patients with ICH. Clinical characteristics were described and stratified by presence of AF. In-hospital and 3-month mortality and 3-month disability were analyzed, considering antithrombotic pretreatment (none, antiplatelets, or oral anticoagulants) and AF (yes/no). Results AF was present in 21.9% of primary ICH cases. Patients with AF-ICH were older, with more vascular risk factors, more antithrombotic pretreatment, higher clinical severity, higher hematoma volume, and higher in-hospital and 3-month mortality. Do-not-resuscitate orders were applied more frequently in AF-ICH cases. After 2 different adjustment models, mortality remained significantly higher in patients with AF-ICH. However, after introducing previous antithrombotic treatment in the model, the adjusted odds ratio for 3-month mortality was 1.45 (95% confidence interval 0.74–2.85, p = 0.284) for patients with AF-ICH compared with non-AF cases. AF modified the effect of antithrombotic pretreatment on in-hospital (pint = 0.077) and 3-month mortality (pint = 0.008). Among patients without AF, antithrombotic pretreatment increased mortality; no effect was observed in patients with AF-ICH. Conclusions Patients with AF and ICH had increased mortality; however, AF had no independent effect on mortality after adjustment for antithrombotic pretreatment. Conversely, antithrombotic pretreatment had a deleterious effect on outcome in patients with ICH without AF, but no detectable effect in patients with AF with ICH.
No takes yet. Share an insight, caveat, or question.
Roquer et al. (2019) conducted an observational in Primary intracerebral hemorrhage (ICH) (n=1,106). Atrial fibrillation and antithrombotic pretreatment vs. No atrial fibrillation was evaluated on 3-month mortality (OR 1.45, 95% CI 0.74-2.85, p=0.284). In patients with intracerebral hemorrhage, atrial fibrillation did not independently increase 3-month mortality after adjusting for antithrombotic pretreatment.
Synapse has enriched 10 related papers. Consider them for comparative context: